1Q EARNINGS: Extraordinary factors help/hinder Takeda as Actos slumps
This article was originally published in Scrip
Executive Summary
Takeda has raised its sales forecast for the current fiscal year ending next 31 March by JPY90.0bn to JPY1,680.0bn ($17.14bn) based on its first quarter performance, exchange rate outlook and the impact of the May acquisition of vaccines firm Inviragen.